Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panorama phase 3 trial of MM120 in adults with generalized anxiety disorder
2024-513572-17-00Phase 3Authorised
- Sponsor
- Definium Therapeutics
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of lysergic acid diethylamide D-tartrate in generalized anxiety disorder (GAD) (3 arms), sponsored by Definium Therapeutics. Primary endpoint: Change from baseline in Hamilton Anxiety Rating Scale total score at Week 12. Planned start Feb 2025; status: authorised.
02
Drugs
lysergic acid diethylamide D-tartrate
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2024-513572-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513572-17-00.